First Header Logo Second Header Logo

Connection

David Caudell to Enzyme Inhibitors

This is a "connection" page, showing publications David Caudell has written about Enzyme Inhibitors.
Connection Strength

0.242
  1. Cook GJ, Caudell DL, Elford HL, Pardee TS. The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML. PLoS One. 2014; 9(11):e112619.
    View in: PubMed
    Score: 0.116
  2. Pardee TS, Gomes E, Jennings-Gee J, Caudell D, Gmeiner WH. Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity. Blood. 2012 Apr 12; 119(15):3561-70.
    View in: PubMed
    Score: 0.096
  3. Regna NL, Vieson MD, Luo XM, Chafin CB, Puthiyaveetil AG, Hammond SE, Caudell DL, Jarpe MB, Reilly CM. Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice. Clin Immunol. 2016 Jan; 162:58-73.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.